Tuesday, 18 Jun 2019

You are here

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders.  A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Subjects from the multicenter Veterans Affairs Rheumatoid Arthritis (VARA) registry were included and assessed for the presence of gout and serum urate (sUA) levels. 

From a total of 1,999 RA patients 17% had elevated sUA levels (>6.8 mg/dl) and 6.1% had a diagnosis of gout.

The presence of moderate hyperuricemia (sUA >6.8‐8 mg/dl) was associated with an increased risk of CVD‐related mortality (HR 1.56; 95% CI 1.11‐2.21), but this association was attenuated and became nonsignificant with adjustments for other comorbidities commonly seen with hyperuricemia. There were no associations of baseline sUA with all‐cause mortality.

Thus there is a small subset of RA patients who may have gout or hyperuricemia and such findings should underscore the need to also manage comorbidities that may contribute to cardiovascular risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.

Despite Gout Numbers and Flares, Allopurinol is Underutilized

A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

Ideal Outcomes are Seldom Achieved in Gout

Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) < 6 mg/dL and remission are rare, especially for those with severe gout.